Skip to content
MarketScale
Demo
‹ Back to IndustriesHealthcare

Network Segmentation: The First Line of Defense in Healthcare’s Cybersecurity Battle

Healthcare systems are adopting network segmentation to isolate critical infrastructure from vulnerable entry points, significantly reducing the impact of breaches and enhancing patient safety. Recent cyberattacks have underscored vulnerabilities in healthcare, making a robust cybersecurity strategy crucial. Without network segmentation, healthcare infrastructure is at increased risk, affecting essential services.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By Robin Berthier, Ph.D. · Dr. Robin BerthierExperts TalkImprovingNetwork Perception
Share

Key takeaways

01

Network segmentation reduces breach impact.

02

Healthcare cybersecurity is a critical concern due to recent attacks.

03

Lack of network segmentation exposes healthcare infrastructure to risks.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Recent cyberattacks, including a major incident at Change Healthcare, have highlighted severe vulnerabilities in healthcare systems, propelling cybersecurity to a critical concern across the industry. In particular, the lack of network segmentation has exposed healthcare infrastructure to increased risk, affecting essential services and compromising patient care. As healthcare institutions continue to integrate more digital technologies, the complexity and scope of their network environments grow, raising the stakes for security measures.

How can healthcare institutions improve network segmentation and reduce cyber risk? How critical is network architecture in safeguarding patient data and healthcare operations?

In the latest episode of MarketScale's premier roundtable show Experts Talk, Dr. Robin Berthier offers a detailed analysis of the current shortcomings in healthcare network security. Drawing on his experience as the CEO and Co-Founder of Network Perception, Dr. Berthier also details strategic steps to enhance protection.

Key takeaways from Dr. Berthier's discussion include:

– The critical need for enhanced network segmentation within healthcare IT environments.

– The role of third-party connections in increasing cybersecurity risks.

– Common vulnerabilities seen in the postmortem analyses of recent healthcare cyberattacks.

– Strategies for healthcare institutions to isolate critical systems from general IT networks.

– The importance of continuous security monitoring and updating to adapt to new threats.

Video TranscriptExpand ↓

The attack surface that we have to protect just expanded in the last five to ten years. Right? That we you know, you you're right. With those VPNs, we're just no longer having to protect our own network. We also have to protect I mean, we also have to consider the the risk that the third parties, the solution providers are bringing to our network through their connectivity. And and for me, what's very surprising whenever I see those, the postmortem on those attacks is just a lack of segmentation between the critical systems and the the general IT admin or email system. And and when a large organization is shutting down those operations, that means a lack of confidence in the way they can segment and and cut off those critical systems from the rest. So so we have a lot to You're hitting you're hitting it. Yeah. Absolutely. There is no segmentation when it comes in IT. In In in in hospitals, it's all in the same data center. They're all in the same VLANs often. There there's really no segmentation. This is our email and and our active directory, and this is our pure medical IT focus driven. I don't that that is not a common thing to do. I've seen it here and there. Folks who take security really serious, and they do patch Tuesday and all that fun stuff. But the segmentation is is is definitely lacking in in a lot of hospitals.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

RB
Robin Berthier, Ph.D.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

The FDA’s interchangeable biosimilar pathway is moving from a one-off insulin milestone to a repeatable playbook for pharmacy-level substitution, with Wezlana (ustekinumab-auub) approved as interchangeable to Stelara in late 2023 and a first interchangeable biosimilar to golimumab reported in September 2026. Evidence from a JAMA Health Forum economic evaluation cited by Podiatry Today found that insulin glargine interchangeability in November 2021 was followed by an immediate jump of more than 47,000 prescriptions for Semglee and insulin glargine-yfgn, suggesting the designation itself can change dispensing behavior. For hospitals, health systems, and payers, the operational consequence shows up less in the FDA letter and more in formulary design, NDC-level claims logic, pharmacy notification requirements that vary by state, and the inventory and education workflows that make substitution predictable instead of chaotic.

  • 01Interchangeability is a workflow change, not a clinical debate. The systems that decide spend are NDC mapping, e-prescribe defaults, and pharmacy switch rules governed by state law.
  • 02The pipeline is widening beyond diabetes. Wezlana’s interchangeability to Stelara (Healthcare Purchasing News) and a newly reported interchangeable golimumab biosimilar (Journal of Healthcare Management/AJN via Ovid) signal more specialty and infusion-adjacent categories will face pharmacy-level substitution decisions.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

RB
Robin Berthier, Ph.D.

For Healthcare teams

See how Healthcare teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›
Keep exploring

More from Healthcare

Healthcare hubMore expert Healthcare coverage.Explore →Executive Thought LeadershipPut clinical leaders on the record.Explore →CooperVisionMedical device storytelling.Explore →State of GEO & AI VisibilityHow B2B brands get cited by AI search.Explore →

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512